# US 2021/0330719 A1 · Probiotic combination for treatment of inflammatory-related gastrointestinal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330719 A1
- Document ID: US20210330719A1
- Status: Published application
- Kind: A1
- Application number: 17/273,635
- Filed: 2019-10-01
- Published: 2021-10-28
- Earliest claimed: 2018-10-02
- Assignees: Societe des Produits Nestle S.A.
- Applicants: Société des Produits Nestlé S.A.
- Inventors: Jalil BENYACOUB; Stéphane DUBOUX; Gail CZARNECKI-MAULDEN; Guénolée Eliane Marie PRIOULT; Gabriela BERGONZELLI DEGONDA
- Web page: https://patentgrep.com/patent/US20210330719A1

## CPC

- A61K 35/745: Bifidobacteria
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a probiotic combination comprising B. longum and B. lactis for the treatment or prevention of an inflammatory-related gastrointestinal disorder such as an inflammatory bowel disease.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

A composition comprising a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.

### Claim 14 (depends on 13)

A composition according to claim 13, wherein said probiotic combination further comprises Bifidobacterium longum ATCC BAA-999.

### Claim 15 (depends on 13)

A composition according to claim 13, wherein the composition comprises each probiotic in the probiotic combination in an amount of 103 to 1012 cfu per gram of the dry weight of the probiotic composition.

### Claim 16 (depends on 13)

A composition according to claim 13, wherein the composition is selected from the group consisting of: a pharmaceutical formulation, a veterinary formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product and a pet care product.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

A method for reducing gastrointestinal inflammation, reinforcing intestinal barrier, or for treating or preventing inflammatory bowel disease in a subject comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination is Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.

### Claim 20 (depends on 19)

A method according to claim 19, wherein the probiotic combination further comprises Bifidobacterium longum ATCC BAA-999.

### Claim 21

A method for prevention of inflammation-induced intestinal barrier dysfunction, reduction of intestinal barrier permeability, improvement of barrier repair, improvement of barrier function and/or reinforcement/protection of intestinal barrier in a subject, comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.

### Claim 22

(canceled)

### Claim 23 (depends on 21)

The method of claim 21, wherein the probiotic combination further comprises Bifidobacterium longum ATCC BAA-999.

### Claim 24

A method for reduction of gastrointestinal inflammation or for treatment or prevention of inflammatory-related gastrointestinal disorders in a subject, comprising the step of administering to said subject a probiotic combination, wherein the probiotic combination comprises Bifidobacterium longum CNCM I-2618 and Bifidobacterium lactis CNCM I-3446.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the probiotic combination further comprises Bifidobacterium longum ATCC BAA-999.

### Claim 26 (depends on 24)

The method according to claim 24, wherein the inflammatory-related gastrointestinal disorder is modulated by a pro-inflammatory and/or anti-inflammatory cytokine; wherein the inflammatory-related gastrointestinal disorder is modulated by IL-10 and/or IL-12; wherein the inflammatory-related gastrointestinal disorder is modulated by T regulatory cells or Th17/Treg differentiation; or wherein the inflammatory-related gastrointestinal disorder is modulated by a quorum sensing signaling inhibitor.

### Claim 27 (depends on 24)

The method according to claim 24, wherein the inflammatory-related gastrointestinal disorder is modulated by an imbalance of beneficial bacteria; wherein the inflammatory-related gastrointestinal disorder is modulated by defensins or mucins; or wherein the inflammatory-related gastrointestinal disorder is modulated by oxidative stress or inflammatory markers such as CRP.

### Claim 28 (depends on 24)

The method according to claim 24, wherein the probiotic composition decreases or suppresses the production or expression of a pro-inflammatory cytokine; increases the production or expression of an anti-inflammatory cytokine and/or decreases or suppresses the production or expression of a pro-inflammatory cytokine; regulates the concentration ratios of IL-10 and IL-12; increases the population of beneficial bacteria in the gut; promotes the production or expression of defensins or mucins; reduces oxidative stress or inflammatory markers; promotes microbiota metabolic function; supports or promotes tissue healing or reinforces or improves gut barrier; improves intestinal barrier repair and/or function; improves or reinforces intestinal barrier permeability; modulates T regulatory cells or Th17/Treg differentiation, promotes T regulatory cell activation or Th17/Treg differentiation; or promotes quorum sensing signaling inhibitors.

### Claim 29 (depends on 24)

The method according to claim 24, wherein the inflammatory-related gastrointestinal disorder is an inflammatory bowel disease, wherein the inflammatory bowel disease is selected from the group consisting of: colitis, ulcerative colitis, chronic enteropathy, Crohn's disease and pouchitis; or wherein the inflammatory-related gastrointestinal disorder is food responsive diarrheal disease.

### Claim 30 (depends on 24)

The method according to claim 24, wherein the inflammatory-related gastrointestinal disorder is ulcerative colitis, Crohn's disease or food responsive diarrhea.

### Claim 31 (depends on 24)

The method according to claim 24, wherein the probiotic composition increases the concentration or expression of an anti-inflammatory cytokine.

### Claim 32 (depends on 24)

The method according to claim 24, wherein the subject is a mammal.

### Claim 33 (depends on 24)

The method according to claim 24, wherein the subject is a human or companion animal.

### Claim 34 (depends on 24)

The method according to claim 24, wherein each probiotic in the probiotic combination is administered to the subject in an amount equating to 108 to 1012 cfu per day.
